

Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **May 1, 2021**, Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the May 1, 2021 updates for complete listings of products available by special authorization, step therapy and special authorization, products with changes to criteria for coverage, added products, Least Cost Alternative (LCA) price changes, products with a price change and discontinued and delisted products.

Please note that the online Interactive Drug Benefit List (iDBL) at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Temporary benefit added to the ADBL

Due to the unavailability of Nestle Materna Tablet (NPN 80082297) manufactured by Nestle Canada Inc., Prenatal 100% Complete Multivitamin Tablet (NPN 80075639) will be considered as a temporary benefit for the ADBL. The following grouping was added to the Critical Supply Product List **April 9, 2021**.

As of **April 9, 2021**, all claims for Prenatal 100% Complete Multivitamin Tablet (NPN 80075639) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

If this situation continues to be a long-term matter, this product will be subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the ADBL to remain as a benefit.

Product supply shortages addressed for ADBL

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage for Mylan-Verapamil SR 240 mg Sustained-Release Tablet (DIN 02450496) has been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 19, 2021**. The following grouping was removed from the Critical Supply Product List **April 19, 2021**.

VERAPAMIL HCL

240 MG SUSTAINED-RELEASE TABLET

00002246895	APO-VERAP SR	APX	\$ 0.5075
00002450496	MYLAN-VERAPAMILSR	MYP	\$ 0.5075
00000742554	ISOPTIN SR	BGP	\$ 2.2944

Alberta Blue Cross has been advised by Apotex Inc, Ranbaxy Pharmaceuticals Canada Inc, and Sivem Pharmaceuticals

continued next page

PHARMACY BENEFACT

continued from previous page

ULC that the shortages for Apo-Lisinopril 20 mg Tablet (DIN 02217511), Ran-Lisinopril 20 mg Tablet (DIN 02294257) and Lisinopril 20 mg Tablet (DIN 02386259), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 19, 2021**. The following grouping was removed from the Critical Supply Product List **April 19, 2021**.

LISINOPRIL

20 MG TABLET

00002217511	APO-LISINOPRIL	APX	\$ 0.1945
00002394499	AURO-LISINOPRIL	AUR	\$ 0.1945
00002386259	LISINOPRIL	SIV	\$ 0.1945
00002294257	RAN-LISINOPRIL	RAN	\$ 0.1945
00002285134	TEVA-LISINOPRIL (TYPE Z)	TEV	\$ 0.1945
00002049384	ZESTRIL	AZC	\$ 0.8241

Alberta Blue Cross has been advised by Jamp Pharma Corporation, Sandoz Canada Inc and Teva Canada Limited that the shortages for Jamp Candesartan-HCT 32 mg/12.5 mg Tablet (DIN 02473259), Sandoz Candesartan Plus 32 mg/12.5 mg Tablet (DIN 02420732) and Teva-Candesartan/HCTZ 32 mg/12.5 mg Tablet (DIN 02395568), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 24, 2021**. The following grouping was removed from the Critical Supply Product List **April 23, 2021**.

CANDESARTAN CILEXETIL/ HYDROCHLOROTHIAZIDE

32 MG / 12.5 MG TABLET

00002421046	AURO-CANDESARTAN HCT	AUR	\$ 0.2156
00002473259	JAMP CANDESARTAN-HCT	JPC	\$ 0.2156
00002420732	SANDOZ CANDESARTAN PLUS	SDZ	\$ 0.2156
00002395568	TEVA-CANDESARTAN/HCTZ	TEV	\$ 0.2156
00002332922	ATACAND PLUS	AZC	\$ 1.3077

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

